A Comparison of CGM estimated hemoglobin A1c in adults with type 1 or type 2 diabetes
Salam M, Bailey R, Calhoun P, et al.
Diabetes Technol Ther. Pub. online 6 Dec 2022.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Impact of expanding access to continuous glucose monitoring systems among insulin users with type 1 or type 2 diabetes
Pathak S, Kearin K, Kahkoska A et al.
Diabetes Technol Ther. Pub. online 8 Dec 2022.
Leggi
Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
Maalmi H, Strom A, Petrera A, et al.
Diabetologia. Pub. online 6 Dec 2022.
Leggi
Associations between diabetic retinopathy, mortality, disease, and mental health: an umbrella review of observational meta-analyses
Trott M, Driscoll R, Pardhan S
BMC Endocr Disord. 2022;22(1):311.
Leggi
Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: A propensity-matched cohort study
Cheung JTK, Yang A, Wu H, et al.
Diabetes Res Clin Pract. Pub. online 6 Dec 2022.
Leggi
Comparison of sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist prescribing in patients with diabetes mellitus with and without cardiovascular disease
Gay HC, Yu J, Persell SD, et al.
Am J Cardiol. 2022;S0002-9149(22)01131-6.
Leggi
Two decades of diabetes prevention efforts: a call to innovate and revitalize our approach to lifestyle change
Golovaty I, Ritchie ND, Tuomilehto J, et al.
Diabetes Res Clin Pract. 2022;110195.
Leggi
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Urva S, Coskun T, Loh MT, et al.
Lancet. 2022;400(10366):1869-1881.
Leggi
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease – analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin
Corbin KD, Dagogo-Jack S, Cannon CP, et al.
Diabetes Obes Metab. 2022 Nov 17.
Leggi
Fully closed-loop insulin delivery in patients undergoing pancreatic surgery
Krutkyte G, Roos J, Schuerch D, et al.
Diabetes Technol Ther. 2022 Nov 30.
Leggi